Catheter Precision Makes NYSE American Section 610(b) Public Announcement
Catheter Precision (NYSE: VTAK), a US medical device company specializing in cardiac electrophysiology products, has made a mandatory public announcement under NYSE American Company Guide Section 610(b). The company disclosed that its audited financial statements for the year ended December 31, 2024, included an independent audit opinion containing a Substantial Doubt Regarding Going Concern paragraph.
This disclosure, previously included in the company's Annual Report on Form 10-K filed March 31, 2025, does not represent any changes or amendments to the consolidated financial statements or the annual report.
Catheter Precision (NYSE: VTAK), un'azienda statunitense specializzata in dispositivi medici per l'elettrofisiologia cardiaca, ha pubblicato un annuncio obbligatorio ai sensi della Sezione 610(b) della Guida per le Società NYSE American. La società ha comunicato che i suoi bilanci revisionati per l'anno chiuso al 31 dicembre 2024 includono un parere di revisione indipendente contenente un paragrafo di Notevole Dubbio sulla Continuità Aziendale.
Questa comunicazione, già presente nel Rapporto Annuale della società sul Modulo 10-K depositato il 31 marzo 2025, non comporta modifiche o integrazioni ai bilanci consolidati o al rapporto annuale.
Catheter Precision (NYSE: VTAK), una empresa estadounidense especializada en dispositivos médicos para electrofisiología cardíaca, ha realizado un anuncio público obligatorio conforme a la Sección 610(b) de la Guía para Empresas de NYSE American. La compañía reveló que sus estados financieros auditados para el año terminado el 31 de diciembre de 2024 incluyen una opinión de auditoría independiente que contiene un párrafo de Duda Sustancial Sobre la Continuidad Operativa.
Esta divulgación, previamente incluida en el Informe Anual de la compañía en el Formulario 10-K presentado el 31 de marzo de 2025, no representa cambios ni enmiendas a los estados financieros consolidados ni al informe anual.
Catheter Precision(NYSE: VTAK)는 심장 전기생리학 제품을 전문으로 하는 미국 의료기기 회사로, NYSE American 회사 안내서 섹션 610(b)에 따라 필수 공시를 했습니다. 회사는 2024년 12월 31일 종료된 회계연도에 대한 감사된 재무제표에 계속기업 존속에 대한 중대한 의문 단락이 포함된 독립 감사 의견이 있음을 공개했습니다.
이 공시는 2025년 3월 31일 제출된 회사의 10-K 연례보고서에 이미 포함되어 있으며, 연결 재무제표나 연례보고서에 대한 변경이나 수정 사항을 의미하지 않습니다.
Catheter Precision (NYSE : VTAK), une entreprise américaine spécialisée dans les dispositifs médicaux en électrophysiologie cardiaque, a publié une annonce publique obligatoire conformément à la section 610(b) du Guide des entreprises NYSE American. La société a révélé que ses états financiers audités pour l'exercice clos au 31 décembre 2024 incluent une opinion d'audit indépendante contenant un paragraphe de Doute Important Concernant la Continuité d'Exploitation.
Cette divulgation, déjà incluse dans le rapport annuel de la société sur le formulaire 10-K déposé le 31 mars 2025, ne représente aucune modification ou amendement aux états financiers consolidés ni au rapport annuel.
Catheter Precision (NYSE: VTAK), ein US-amerikanisches Medizintechnikunternehmen, das sich auf Produkte der kardialen Elektrophysiologie spezialisiert hat, hat eine verpflichtende öffentliche Bekanntmachung gemäß Abschnitt 610(b) des NYSE American Company Guide veröffentlicht. Das Unternehmen gab bekannt, dass seine geprüften Jahresabschlüsse für das am 31. Dezember 2024 endende Geschäftsjahr eine unabhängige Prüfungsmeinung mit einem Absatz Erhebliche Zweifel an der Fortführung enthalten.
Diese Offenlegung, die bereits im Jahresbericht des Unternehmens im Formular 10-K vom 31. März 2025 enthalten war, stellt keine Änderungen oder Ergänzungen der konsolidierten Abschlüsse oder des Jahresberichts dar.
- None.
- Auditors expressed substantial doubt about company's ability to continue as going concern
- Significant financial viability concerns indicated by the audit opinion
Fort Mill, S.C., April 17, 2025 (GLOBE NEWSWIRE) -- -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, announced today that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024, filed March 31, 2025, with the Securities and Exchange Commission, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a Substantial Doubt Regarding Going Concern paragraph. See further discussion in footnote 1 to the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K.
This announcement is made pursuant to NYSE American Company Guide Section 610(b), which requires separate public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Company's consolidated financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2024.
CONTACTS:
At the Company
David Jenkins
973-691-2000
info@catheterprecision.com
FAQ
What does the going concern warning mean for Catheter Precision (VTAK) investors?
When did Catheter Precision (VTAK) receive the going concern audit opinion?
What are the NYSE American Section 610(b) requirements for Catheter Precision (VTAK)?
Will the going concern announcement affect Catheter Precision's (VTAK) NYSE American listing?
